ISOFOL — Isofol Medical AB (publ) Income Statement
0.000.00%
Last trade - 00:00- SEK306.72m
- SEK210.56m
Annual income statement for Isofol Medical AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 37.1 | 22.4 | 12.8 | 0.721 | 0 |
| Cost of Revenue | |||||
| Gross Profit | -162 | -174 | -131 | -34.4 | -38.7 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 224 | 227 | 180 | 42.4 | 47.2 |
| Operating Profit | -186 | -204 | -168 | -41.7 | -47.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -189 | -200 | -160 | -37.1 | -43.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -189 | -200 | -160 | -37.1 | -43.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -189 | -200 | -160 | -37.1 | -43.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -189 | -200 | -160 | -37.1 | -43.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.43 | -1.59 | -0.989 | -0.23 | -0.269 |
| Dividends per Share |